For example, TRIM25 activates NRF2 and promotes the progression of hepatocellular carcinoma [28], regulates the stability of EZH2, thereby promoting the resistance of colorectal cancer to oxaliplatin [43]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.